# Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

> **NCT02479087** · PHASE4 · UNKNOWN · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 20 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Plasma-derived FVIII/VWF concentrate

## Key facts

- **NCT ID:** NCT02479087
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2019-01
- **Final completion:** 2020-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2015-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479087, "Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02479087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*